title: Baseline predictors of A1C reduction in adults using sensor-augmented pump therapy or multiple daily injection therapy: the STAR 3 experience.
abstract: BACKGROUND
  Baseline characteristics from the adult cohort of a randomized controlled trial comparing sensor-augmented pump (SAP) and multiple daily injection (MDI) therapy were analyzed for significant relationships with -0.5% A1C change at 1 year of therapy without incidence of severe hypoglycemia (defined as A1C benefit).
  
  
  METHODS
  Baseline characteristics were compared with A1C benefit. Statistically significant predictors were analyzed further to determine appropriate cutpoints of relative A1C benefit.
  
  
  RESULTS
  Baseline A1C ≥9.1%, age at randomization ≥36 years, and age at diabetes diagnosis of ≥17 years were associated with a greater SAP benefit relative to MDI than other cutpoints.
  
  
  CONCLUSIONS
  People with type 1 diabetes who had a high A1C and who were older at diagnosis and older at randomization experienced the most benefit from SAP therapy.
authors.affiliation: Division of Endocrinology and Metabolism, University of North Carolina School of Medicine, Chapel Hill, North Carolina, USA. jbuse@med.unc.edu
authors.forename: John B
authors.initials: JB
authors.lastname: Buse
authors.forename: George
authors.initials: G
authors.lastname: Dailey
authors.forename: Andrew A
authors.initials: AA
authors.lastname: Ahmann
authors.forename: Richard M
authors.initials: RM
authors.lastname: Bergenstal
authors.forename: Jennifer B
authors.initials: JB
authors.lastname: Green
authors.forename: Tim
authors.initials: T
authors.lastname: Peoples
authors.forename: Robert J
authors.initials: RJ
authors.lastname: Tanenberg
authors.forename: Qingqing
authors.initials: Q
authors.lastname: Yang
mesh_terms: D000293:Adolescent; D000328:Adult; D000367:Age Factors; D000368:Aged; D002648:Child; D015331:Cohort Studies; D003922:Diabetes Mellitus, Type 1 / Q000097:blood* / Q000188:drug therapy*; D005260:Female; D006442:Glycated Hemoglobin / Q000032:analysis*; D006801:Humans; D006943:Hyperglycemia / Q000517:prevention & control*; D007004:Hypoglycemic Agents / Q000008:administration & dosage* / Q000627:therapeutic use; D007328:Insulin / Q000008:administration & dosage* / Q000627:therapeutic use; D007332:Insulin Infusion Systems; D008297:Male; D008422:Materials Testing; D008875:Middle Aged; D008954:Models, Biological; D016896:Treatment Outcome; D055815:Young Adult
chemical_list: D006442:Glycated Hemoglobin; D007004:Hypoglycemic Agents; D007328:Insulin; C517652:hemoglobin A1c protein, human